Adagene Inc. (ADAG) NASDAQ

3.36

-0.035(-1.03%)

Updated at June 03 12:02PM

Currency In USD

Key Executives

Name	Title	Year Born
Peter Luo	Co- Founder, Chairman, Chief Executive Officer and President of R&D	1966
Man Kin Tam	Chief Financial Officer & Director	1977
Jiping Zha	Executive Vice President of Clinical Development	N/A
Songmao Zheng	Senior Vice President of Clinical Pharmacology & Quantitative Sciences	N/A
Alexander Goergen	Vice President & Head of Business Development	1987
Guizhong Liu	Senior Vice President of Early Drug Discovery	1971
Mickael Chane-Du	Chief Strategy Officer	N/A
Yan Li	Senior Vice President of Bioinformatics & Information Technology	1975
Qinghai Zhao	Chief Manufacturing Officer	1961
Chunfang Gu	Executive Director of Finance	N/A
Xiaohong She	Senior Vice President & Head of Clinical Operations	1967
Ling Zhou	Executive Director & Head of Human Resources	N/A

Name

Title

Pay

Year Born

Peter Luo

Co- Founder, Chairman, Chief Executive Officer and President of R&D

1966

Man Kin Tam

Chief Financial Officer & Director

1977

Jiping Zha

Executive Vice President of Clinical Development

N/A

Songmao Zheng

Senior Vice President of Clinical Pharmacology & Quantitative Sciences

N/A

Alexander Goergen

Vice President & Head of Business Development

1987

Guizhong Liu

Senior Vice President of Early Drug Discovery

1971

Mickael Chane-Du

Chief Strategy Officer

N/A

Yan Li

Senior Vice President of Bioinformatics & Information Technology

1975

Qinghai Zhao

Chief Manufacturing Officer

1961

Chunfang Gu

Executive Director of Finance

N/A

Xiaohong She

Senior Vice President & Head of Clinical Operations

1967

Ling Zhou

Executive Director & Head of Human Resources

N/A

Description

Adagene Inc., a clinical stage biopharmaceutical company, engages in the research, development, and production of monoclonal antibody drugs for cancers. The company's product candidates include ADG106, a human ligand-blocking agonistic anti-CD137 monoclonal antibodies (mAbs) that is in Phase 1b/2 clinical trials for the treatment advanced solid tumors and non-Hodgkin's lymphoma; ADG126, a fully-human anti-CTLA-4 mAb that is in Phase 1 clinical trial for the treatment advanced/metastatic solid tumors; and ADG116, a human ligand-blocking anti-CTLA-4 mAb, which is in Phase I clinical trial for the treatment of advanced metastatic solid tumors. It also offers ADG104, an anti-PD-L1 mAb that is in Phase 2 clinical development; ADG125, a novel anti-CSF-1R mAb, which is in Phase I clinical trial; ADG206, a masked, Fc engineered anti-CD137 agonistic POWERbody, which is in preclinical; ADG153, a masked anti-CD47 IgG1 SAFEbody, which is in preclinical stage for the treatment hematologic and solid tumors; ADG138, novel HER2xCD3 POWERbody, which is in preclinical for the treatment HER2-expressing solid tumors; and ADG152, a CD20xCD3 POWERbody, which is in preclinical stage for the treatment off-tumor toxicities. The company was incorporated in 2011 and is headquartered in Suzhou, China.